ES2688084T3 - Derivados de triazol condensados como inhibidores de fosfodiesterasa 10A - Google Patents

Derivados de triazol condensados como inhibidores de fosfodiesterasa 10A Download PDF

Info

Publication number
ES2688084T3
ES2688084T3 ES15730261.3T ES15730261T ES2688084T3 ES 2688084 T3 ES2688084 T3 ES 2688084T3 ES 15730261 T ES15730261 T ES 15730261T ES 2688084 T3 ES2688084 T3 ES 2688084T3
Authority
ES
Spain
Prior art keywords
compounds
formula
triazolo
compound
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15730261.3T
Other languages
English (en)
Spanish (es)
Inventor
Rafal Moszczynski-Petkowski
Lukasz Bojarski
Maciej Wieczorek
Jakub MAJER
Sylwia JANOWSKA
Mikolaj MATLOKA
Malgorzata BORKOWSKA
Filip Stefaniak
Monika Lamparska-Przybysz
Krzysztof DUBIEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celon Pharma SA
Original Assignee
Celon Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma SA filed Critical Celon Pharma SA
Application granted granted Critical
Publication of ES2688084T3 publication Critical patent/ES2688084T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Lubricants (AREA)
ES15730261.3T 2014-05-19 2015-05-14 Derivados de triazol condensados como inhibidores de fosfodiesterasa 10A Active ES2688084T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL408251A PL408251A1 (pl) 2014-05-19 2014-05-19 Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
PL40825114 2014-05-19
PCT/IB2015/053549 WO2015177688A1 (en) 2014-05-19 2015-05-14 Fused triazole derivatives as phosphodiesterase 10a inhibitors

Publications (1)

Publication Number Publication Date
ES2688084T3 true ES2688084T3 (es) 2018-10-30

Family

ID=53434395

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15730261.3T Active ES2688084T3 (es) 2014-05-19 2015-05-14 Derivados de triazol condensados como inhibidores de fosfodiesterasa 10A

Country Status (17)

Country Link
US (1) US10138245B2 (Direct)
EP (1) EP3145930B1 (Direct)
JP (1) JP6455947B2 (Direct)
KR (1) KR102404650B1 (Direct)
CN (1) CN106459060B (Direct)
AU (1) AU2015263013B2 (Direct)
CA (1) CA2946258C (Direct)
DK (1) DK3145930T3 (Direct)
EA (1) EA030330B9 (Direct)
ES (1) ES2688084T3 (Direct)
HR (1) HRP20181027T1 (Direct)
HU (1) HUE039847T2 (Direct)
MX (1) MX367647B (Direct)
PL (2) PL408251A1 (Direct)
PT (1) PT3145930T (Direct)
SI (1) SI3145930T1 (Direct)
WO (1) WO2015177688A1 (Direct)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017007301A1 (en) * 2015-07-06 2017-01-12 Universiti Sains Malaysia Compound and method for inhibiting sirtuin activities
KR102587382B1 (ko) * 2016-04-29 2023-10-12 솔루스첨단소재 주식회사 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자
CN111410657B (zh) * 2019-01-08 2024-05-21 北京鼎材科技有限公司 一种发光材料及其应用
WO2025160629A1 (en) * 2024-01-31 2025-08-07 Certa Therapeutics Pty Ltd Proton sensing gpcr modulators
US20250276984A1 (en) * 2024-02-20 2025-09-04 Iambic Therapeutics, Inc. Solid state forms of her2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011893A2 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
US8975276B2 (en) * 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10

Also Published As

Publication number Publication date
EP3145930A1 (en) 2017-03-29
CA2946258A1 (en) 2015-11-26
HRP20181027T1 (hr) 2018-08-24
MX367647B (es) 2019-08-29
CN106459060B (zh) 2019-04-05
PL408251A1 (pl) 2015-11-23
WO2015177688A1 (en) 2015-11-26
HUE039847T2 (hu) 2019-02-28
JP2017521364A (ja) 2017-08-03
PT3145930T (pt) 2018-10-11
EA030330B9 (ru) 2018-09-28
AU2015263013A1 (en) 2016-11-17
SI3145930T1 (sl) 2018-10-30
KR102404650B1 (ko) 2022-06-02
JP6455947B2 (ja) 2019-01-23
MX2016015180A (es) 2017-03-23
DK3145930T3 (en) 2018-09-24
EA201692264A1 (ru) 2017-04-28
KR20170005860A (ko) 2017-01-16
CA2946258C (en) 2023-06-06
CN106459060A (zh) 2017-02-22
US20170114064A1 (en) 2017-04-27
PL3145930T3 (pl) 2018-11-30
EP3145930B1 (en) 2018-07-04
EA030330B1 (ru) 2018-07-31
US10138245B2 (en) 2018-11-27
AU2015263013B2 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
ES2688084T3 (es) Derivados de triazol condensados como inhibidores de fosfodiesterasa 10A
CA2865957C (en) Compounds for treating spinal muscular atrophy
CA2868026C (en) Compounds for treating spinal muscular atrophy
US9399649B2 (en) Compounds for treating spinal muscular atrophy
CA2863874C (en) Compounds for treating spinal muscular atrophy
CA2861609C (en) Compounds for treating spinal muscular atrophy
CN109721620A (zh) Hpk1抑制剂及其用途
ES2838004T3 (es) Inhibidores de cinasa relacionada con tropomiosina (TRK)
JP2018519273A (ja) 脊髄性筋萎縮症を処置するための化合物
CA3219925A1 (en) Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
CN118084916A (zh) 三并杂环类化合物及其用途
US20240368188A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
BR112016027023B1 (pt) Derivados de triazol fundidos como inibidores de fosfodiesterase 10a
WO2024220633A1 (en) Pyrrolopyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4
KR20250172652A (ko) 신경학적 및 정신의학적 장애의 치료에 유용한 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서의 1,6-나프티리딘 유도체
JPWO2000034277A1 (ja) スルホンアミド化合物およびその医薬用途